We are testing a new gene therapy for people with no light perception due to end-stage rod cone dystrophy. The study aims to assess the safety and tolerability of a single injection in those who still have dormant cone photoreceptors.
Health conditions and diseases that the clinical trial is designed to study and treat.
Hereditary retinal dystrophy is a group of genetic disorders that cause progressive degeneration of the retina, leading to vision loss. Symptoms may include difficulty seeing at night, loss of peripheral vision, and eventual loss of central vision.
End-stage rod-cone dystrophy is a severe form of hereditary retinal dystrophy where the rod and cone photoreceptors in the retina are significantly damaged, leading to profound vision loss.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.